CA-ESRI
5.10.2021 15:02:11 CEST | Business Wire | Press release
Global construction challenges, from affordable housing availability to infrastructure stress as a result of climate change, have increased in recent years. As a result, governments and commercial organizations will need to invest trillions of dollars in the next decade in mitigation and recovery processes. By adopting building information modeling (BIM) and geographic information system (GIS) technology, the architecture, engineering, and construction (AEC) industry improved construction, design, and operations efficiency. Recognizing the benefits for project outcomes that a combined BIM and GIS software would present, Esri , the global leader in location intelligence, joined forces with Autodesk in 2017. The partnership produced new technology, integrating the power of mapping into the BIM process.
Today, Esri is releasing a new product that expands the ability for BIM project teams to benefit from GIS. ArcGIS GeoBIM provides an innovative, easy-to-use web-based experience for AEC teams to explore and collaborate using data from multiple systems in a geospatial context. ArcGIS GeoBIM connects to Autodesk BIM Collaborate Pro , a cloud-based design collaboration, coordination, and model coauthoring software built on the Autodesk Construction Cloud .
"With many global initiatives under way to improve construction, design, and planning practices, it is critical that today's AEC professionals can collaborate together with a common view of assets in a geospatial context," said Jack Dangermond, Esri founder and president. "The ability to operate without siloed data provides AEC professionals with the flexibility they need to work together and meet the challenges of building in the future on an unprecedented scale."
ArcGIS GeoBIM will provide project leaders and stakeholders in industries like infrastructure, construction, planning, water, and transportation with a common view of asset locations, costs, issues, risks, and timelines throughout the project life cycle.
"Autodesk and Esri's cloud-to-cloud connection gives our shared customers a unified experience and the information they need at their fingertips—regardless of whether it's BIM or GIS data," said Amy Bunszel, Autodesk executive vice president of AEC Design Solutions. "This will improve efficiency and decision-making during planning, construction, and operations. Ultimately, our collaboration will help enable the industry to deliver more sustainable and resilient infrastructure."
AEC team members can track design, coordination, quality, safety, and commissioning issues by linking data from Autodesk BIM Collaborate with ArcGIS GeoBIM.
"What we need is a single, authoritative source of truth access point for everyone on our team, a way to bring data and information together that originates from multiple formats," said Darin Welch, HNTB associate vice president and national geospatial and virtual engagement manager. "Esri's ArcGIS GeoBIM connection to the Autodesk Construction Cloud combines survey, design, and planning workflows that offer a blended BIM-GIS data experience that equips our team with more informed decision-making."
ArcGIS GeoBIM is available for widespread use as of October 4, 2021. For more information and to stay up-to-date on the latest offerings, visit go.esri.com/geobim-pr .
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2021 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, GeoBIM, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
Autodesk and Autodesk Construction Cloud are registered trademarks of Autodesk, Inc., in the USA and/or other countries .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005638/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom